Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods

[1] Latimer NR(2016)Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy Cancer Med 5 806-815

[2] Bell H(2016)Treatment switching: statistical and decision-making challenges and approaches Int J Technol Assess Health Care 32 160-166

[3] Abrams KR(2015)Adjusting for the confounding effects of treatment switching—the BREAK-3 trial: dabrafenib versus dacarbazine Oncologist. 20 798-805

[4] Amonkar MM(2015)Treatment switching in oncology trials and the acceptability of adjustment methods Expert Rev Pharmacoecon Outcomes Res. 15 561-564

[5] Casey M(1991)Correcting for noncompliance in randomized trials using rank preserving structural failure time models Commun Stat Theory Methods 20 2609-2631

[6] Latimer NR(2002)Estimating a treatment effect in survival studies in which patients switch treatment Stat Med 21 2449-2463

[7] Henshall C(2000)Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests Biometrics 56 779-788

[8] Siebert U(2014)Adjusting survival time estimates to account for treatment switching in randomized controlled trials—an economic evaluation context: methods, limitations, and recommendations Med Decis Mak 34 387-402

[9] Bell H(1996)Epidemiology of multiple sclerosis Neurol Clin 14 291-308

[10] Latimer NR(2002)Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology. 58 169-178

[1] Latimer NR(2016)Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy Cancer Med 5 806-815

[2] Bell H(2016)Treatment switching: statistical and decision-making challenges and approaches Int J Technol Assess Health Care 32 160-166

[3] Abrams KR(2015)Adjusting for the confounding effects of treatment switching—the BREAK-3 trial: dabrafenib versus dacarbazine Oncologist. 20 798-805

[4] Amonkar MM(2015)Treatment switching in oncology trials and the acceptability of adjustment methods Expert Rev Pharmacoecon Outcomes Res. 15 561-564

[5] Casey M(1991)Correcting for noncompliance in randomized trials using rank preserving structural failure time models Commun Stat Theory Methods 20 2609-2631

[6] Latimer NR(2002)Estimating a treatment effect in survival studies in which patients switch treatment Stat Med 21 2449-2463

[7] Henshall C(2000)Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests Biometrics 56 779-788

[8] Siebert U(2014)Adjusting survival time estimates to account for treatment switching in randomized controlled trials—an economic evaluation context: methods, limitations, and recommendations Med Decis Mak 34 387-402

[9] Bell H(1996)Epidemiology of multiple sclerosis Neurol Clin 14 291-308

[10] Latimer NR(2002)Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology. 58 169-178